Merck Sharp + Dohme Corp.

Ortho-Mcneil Pharmaceutical Corp.

Janssen Pharmaceutica Nv

Ligand Pharmaceuticals, Inc.

Other

Ortho Pharmaceutical Corporation

Barbara A Pio

James Patrick Edwards

Jianmei Wei

Steven P Meduna

Hui Cai

Harry R Chobanian

Cheryl A Grice

Haripada Khatuya

Haifeng Tang

Darin J Gustin

Kevin L Tays

Alexander Pasternak

J Guy Breitenbucher

Shawn P Walsh

Yan Guo

Mary Pat Beavers

Aurash Shahripour

Michael W Miller

Jessica Frie

Dong Xiao

Jinlong Jiang

Dooseop Kim

Shuzhi Dong

Christopher W Plummer

Lars Karlsson

Timothy Allen Blizzard

Robin L Thurmond

Lin Zhi

Zhicai Wu

Fa-Xiang Ding

Duane E DeMong

Helen Y Chen

Bharat Lagu

Tesfaye Biftu

Lihu Yang

William K Hagmann

Hubert B Josien

Curt A Dvorak

Chandravadan R Shah

Nicholas I Carruthers

Shuwen He

Zhi-Cai Shi

Santhosh Francis Neelamkavil

Kiev S Ly

Peter H Fuller

Kevin Michael Belyk

Jill A Jablonowski

Clark A Sehon

Vladimir Simov

Jinsong Hao

Cangming Yang

Hua Zhou

William J Greenlee

Christopher Michael Tegley

Esther Martinborough

Ravi P Nargund

Luc J Farmer

Paul E Finke

Jennifer Diane Venable

Bin Hu

Qun Dang

Joey Lee Methot

Wenying Chai

Timothy W Lovenberg

Solomon D Kattar

Harold B Wood

Gregori J Morriello

Bowei Wang

Purakkattle J Biju

Derun Li

Nunzio Sciammetta

Jing Su

Linus S Lin

Xin Gu

Bing Li

Cornelis Arjan Van Oeveren

Wei Xiao

Robert Higuchi

Timothy A Blizzard

Zhengxia Chen

Linda Brockunier

Blair T Lapointe

Weiguo Liu

Yi-Heng Chen

Hakan Gunaydin

John J Acton, Iii

Min Lu

Yuping Zhu

Meibi Dai

Mihir Mandal

Thomas A Bara

Qinghong Fu

Alejandro Crespo

Sarah J West

Zhiyong Hu

Jason W Szewczyk

Rui Zhang

Dann Parker

Matthew John Clements

Ming Wang

The present invention is directed to substituted certain 1-pyrazolyl, 5-, 6-disubstituted indazole derivatives of Formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, and ring A are as defined herein, which are potent inhibitors of LRRK2 kinase and may be useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease and other diseases and disorders described herein. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of diseases, such as Parkinson's disease, in which LRRK-2 kinase is involved.

1-pyrazolyl, 5-, 6-disubstituted indazole derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof

The present invention is directed to substituted certain reversed indazole compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein R, R, X, Y, Rand Rare as defined herein, which are potent inhibitors of LRRK2 kinase and useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease and other diseases and disorders described herein. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved. 

Indazolyl-spiro[2.3]hexane-carbonitrile derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof

Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia. 

Antidiabetic heterocyclic compounds

Antidiabetic spirochroman compounds

Antidiabetic bicyclic compounds

Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.

Antidiabetic compounds

The present invention provides compounds of Formula (I) (Formula (I)) including pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention. 

Inhibitors of the renal outer medullary potassim channel

The present invention relates to a compound represented by formula (I): and pharmaceutically acceptable salts thereof. The compounds of formula I are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia. 

Antidiabetic substituted heteroaryl compounds

The present invention provides compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.

Inhibitors of the renal outer medullary potassium channel

The present invention provides compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure, kidney disease, edema, and conditions associated with excessive salt and water retention.

The present invention provides compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and conditions associated with excessive salt and water retention.

This invention relates to compounds having structural Formula I: and pharmaceutically acceptable salts thereof which are inhibitors of the Renal Outer Medullary Potassium (ROMK) channel (Kir1.1). The compounds of Formula I are useful as diuretics and natriuretics and therefore are useful for the therapy and prophylaxis of disorders resulting from excessive salt and water retention, including cardiovascular diseases such as hypertension and chronic and acute heart failure.

Compounds of the invention, which may be useful in inhibiting thrombin and associated thrombotic occlusions, have the following structure: or a pharmaceutically acceptable salt thereof, wherein

Thrombin inhibitors

Growing community of inventors

San Diego, CA, United States of America

Barbara A Pio